Synonym
Damoctocog alfa pegol
IUPAC/Chemical Name
S-(1-(7-(2-methoxyethoxy)-14-oxo-2,5,9-trioxa-13-azahexadecan-16-yl)-2,5-dioxopyrrolidin-3-yl)-L-cysteine
InChi Key
UGQOPAJHKRJXBG-ADKAHSJRSA-N
InChi Code
InChI=1S/C22H39N3O10S/c1-31-8-10-34-14-16(35-11-9-32-2)13-33-7-3-5-24-19(26)4-6-25-20(27)12-18(21(25)28)36-15-17(23)22(29)30/h16-18H,3-15,23H2,1-2H3,(H,24,26)(H,29,30)/t16?,17-,18?/m0/s1
SMILES Code
COCCOCC(OCCOC)COCCCNC(CCN1C(CC(C1=O)SC[C@@H](C(O)=O)N)=O)=O
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
to be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
|
Solvent |
mg/mL |
mM |
| Solubility |
| To be determined |
0.0 |
100.00 |
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.
Preparing Stock Solutions
The following data is based on the
product
molecular weight
537.63
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Paik J, Deeks ED. Damoctocog Alfa Pegol: A Review in Haemophilia A. Drugs. 2019 Jul;79(10):1147-1156. doi: 10.1007/s40265-019-01152-7. Erratum in: Drugs. 2019 Aug 23;: PMID: 31218660; PMCID: PMC6711950.
2: Paik J, Deeks ED. Correction to: Damoctocog Alfa Pegol: A Review in Haemophilia A. Drugs. 2019 Sep;79(13):1495. doi: 10.1007/s40265-019-01190-1. Erratum for: Drugs. 2019 Jul;79(10):1147-1156. PMID: 31444769; PMCID: PMC6728279.
3: Solms A, Shah A, Berntorp E, Tiede A, Iorio A, Linardi C, Ahsman M, Mancuso ME, Zhivkov T, Lissitchkov T. Direct comparison of two extended half-life PEGylated recombinant FVIII products: a randomized, crossover pharmacokinetic study in patients with severe hemophilia A. Ann Hematol. 2020 Nov;99(11):2689-2698. doi: 10.1007/s00277-020-04280-3. Epub 2020 Sep 24. PMID: 32974838; PMCID: PMC7536163.
4: Fujii T, Kidoguchi Y, Takahashi N, Yu E, Ainiwaer D, Byrne A. Budget impact analysis of Jivi (damoctocog alfa pegol, Bay 94-9027) in severe hemophilia A in Japan. J Med Econ. 2021 Jan-Dec;24(1):218-225. doi: 10.1080/13696998.2021.1875788. PMID: 33459088.
5: Mancuso ME, Reding MT, Negrier C, Kerlin BA, Rangarajan S, Simpson ML. Decreased Bleeding Rates in Patients with Hemophilia A Switching from Standard- Half-Life FVIII to BAY 94-9027 Prophylaxis. Thromb Haemost. 2020 Dec 9. doi: 10.1055/a-1333-5536. Epub ahead of print. PMID: 33296943.
6: Reding MT, Pabinger I, Lalezari S, Santagostino E, Mancuso ME. Target joint resolution in patients with haemophilia A receiving long-term prophylaxis with BAY 94-9027. Haemophilia. 2020 Jul;26(4):e201-e204. doi: 10.1111/hae.13982. Epub 2020 Jun 23. PMID: 32578323; PMCID: PMC7496507.
7: Benson G, Morton T, Thomas H, Lee XY. Long-Term Outcomes of Previously Treated Adult and Adolescent Patients with Severe Hemophilia A Receiving Prophylaxis with Extended Half-Life FVIII Treatments: An Economic Analysis from a United Kingdom Perspective. Clinicoecon Outcomes Res. 2021 Jan 18;13:39-51. doi: 10.2147/CEOR.S280574. PMID: 33500640; PMCID: PMC7822074.
8: Hakimi Z, Santagostino E, Postma MJ, Nazir J. Recombinant FVIIIFc Versus BAY 94-9027 for Treatment of Patients with Haemophilia A: Comparative Efficacy Using a Matching Adjusted Indirect Comparison. Adv Ther. 2021 Feb;38(2):1263-1274. doi: 10.1007/s12325-020-01599-1. Epub 2020 Dec 30. PMID: 33377987; PMCID: PMC7889532.
